The positive interim data from the bladder cancer study could be seen as a positive development for Protara Therapeutics, indicating potential for future success of the TARA-002 program. However, the announcement of a $45M equity raise, while providing necessary capital, may dilute existing shareholders, contributing to the short-term negative price action. The alignment with the FDA on IV Choline Chloride represents a significant regulatory milestone, potentially opening up a new treatment avenue and revenue stream. The mixed nature of these developments leads to a neutral short-term impact score.